Skip to content

Depression: all studies

Page 787 of 1,037: studies 7,861 to 7,870 of 10,363, newest first. Back to the depression overview

Research

Dreaming of the sleep lab

PLoS One October 6, 2021 Claudia Picard-Deland, Tore Nielsen, Michelle Carr 27 citations

The phenomenon of dreaming about the laboratory when participating in a sleep study is common. The content of such dreams draws upon episodic memory fragments of the participant's lab experience, generally, experimenters, electrodes, the lab setting, and experimental tasks. However, as common as such dreams are, they have rarely been given a thorough quantitative or qualitative treatment. Here...

Reply: Variability in motor threshold

Brain Stimulation October 5, 2021 Gonçalo Cotovio, Albino J Oliveira-Maia, Carter Paul et al. 3 citations

Funding Information: GC was funded by Funda??o para a Ci?ncia e Tecnologia (FCT; Portugal) through a PhD Scholarship (SFRH/BD/130210/2017). AJO-M was funded by FCT (Portugal) through a Junior Research and Career Development Award from the Harvard Medical School ? Portugal Program (HMSP-ICJ/0020/2011). GC and AJO-M were supported by grant PTDC/MED-NEU/31331/2017, and AJO-M by grant...

DOI: 10.1016/j.brs.2021.09.012 (opens in new tab) Scopus Depression economics Randomized controlled trial Brain stimulation +3

Delix to synthesize psychedelic drugs

C&EN Global Enterprise October 4, 2021 Ryan Cross

Delix Therapeutics has raised $70 million in series A financing to develop therapies inspired by psychedelics to treat neuropsychiatric and neurodegenerative diseases. The Boston-based start-up joins a list of more than a dozen drug companies developing psychedelic-based therapies for mental illnesses . CEO Mark Rus says Delix is part of a "psychedelic renaissance," in which doctors,...

DOI: 10.1021/cen-09936-buscon3 (opens in new tab) Psilocybin Serendipity Mainstream The renaissance +2

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Frontiers in Psychiatry October 4, 2021 Maxemiliano V. Vargas, Retsina Meyer, Arabo A. Avanes et al. 162 citations

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse...

Uso da psilocibina como ferramenta psicoterapêutica no tratamento da depressão: uma revisão

Scire Salutis October 2, 2021 Joveni Ribeiro da Silva, Sara Mateus da Costa, Diego Pereira da Silva

A psilocibina é uma substância com efeitos psicoativos que está presente em cogumelos do gênero psilocybe. Segundo Griffiths et al. (2011) o uso da psilocibina é percebido como uma experiência espiritual e mística, positiva e agradável. O efeito da psilocibina é influenciado pelo estado mental, experiências anteriores ao uso, dimensão da personalidade e condições ambientais. O objetivo desse...

Commentary on Hearing voices and other matters of mind: What mental abnormalities teach us about religions by Robert McCauley and George Graham

Religion, Brain & Behavior October 2, 2021 R. Bentall

As a recent survey of religious artifacts in the British Museum attests (MacGregor, 2018), religions exist in enormous varieties and have been ubiquitous globally and throughout history. This observation has led to the creation of the subdiscipline of psychology focused on religion which, although not as well-established as older subdisciplines such as social, cognitive and developmental...

Association of mindfulness with psychological distress and life satisfaction in Western and Eastern meditators

Australian Journal of Psychology October 2, 2021 Lakshmi Haranath Somaraju, Elizabeth C. Temple, Lewis A. Bizo et al. 6 citations

Objective This study investigated if meditators living in India (Eastern Meditators: EMs) differed from those living in Western countries (WMs) in self-reported levels of mindfulness, depression, anxiety, stress, and life satisfaction and the association between these variables. Method The 229 participants (18–81 years, M = 34.7 years, SD = 13.3; 52% EMs) completed scales measuring depression,...

Ketamine triggers rapid antidepressant effects by modulating synaptic plasticity in a new depressive-like mouse model based on astrocyte glutamate transporter GLT-1 knockdown in infralimbic cortex.

Revista de Psiquiatría y Salud Mental October 1, 2021 M. N. Fullana, Verónica Paz, Francesc Artigas et al.

OBJECTIVE Recently, we reported on a new MDD-like mouse model based on a regionally selective knockdown of astroglial glutamate transporters, GLAST/GLT-1, in infralimbic cortex (IL) which evokes widespread changes in mouse brain associated with the typical alterations found in MDD patients. To further characterize this new MDD-like mouse model, here we examine some transcriptional elements of...

The Response of EEG Signal on Brain Relaxation Meditation Using Different Type of Zikr

Journal of Physics, Conference Series October 1, 2021 N N Abd Razak, K A Sidek, K Y D Alaa et al.

Abstract: Depression and stress are increasingly prevalent in today’s society, owing to people’s hectic, competitive, and demanding lifestyles. These illnesses had become very common, particularly among young and middle-aged people, and suicidal ideation had been identified as one of the leading causes of death by the World Health Organization (WHO). Nature sound (sound of downpours or beach)...

Putting mindfulness-based cognitive therapy to the test in routine clinical practice: A transdiagnostic panacea or a disorder specific intervention?

Journal of Psychiatric Research October 2021 Dirk E. M. Geurts, N Marlou Haegens, Marleen H.C.T. van Beek et al.

Over the past two decades there has been a growing number of randomized clinical trials supporting the efficacy of mindfulness-based cognitive therapy (MBCT) in the treatment of several psychiatric disorders. Since evidence for its effectiveness in routine clinical practice is lagging behind, we aimed to examine adherence, outcome and predictors of MBCT in a well-characterized, heterogeneous...